source
- J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BThe buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.BioPharma Dive · 1mo ago↗ source
- Treeline to go public via reverse merger with Standard BioToolsTreeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. TheEndpoints · 1mo ago↗ source
- ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionAt a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.BioPharma Dive